Crossmark Global Holdings Inc. Has $5.90 Million Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK)

Crossmark Global Holdings Inc. lifted its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 88.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 396,833 shares of the company's stock after buying an additional 186,349 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Takeda Pharmaceutical were worth $5,901,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. FNY Investment Advisers LLC bought a new stake in shares of Takeda Pharmaceutical in the 1st quarter valued at approximately $37,000. Farther Finance Advisors LLC grew its stake in Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after buying an additional 1,976 shares during the last quarter. Crowley Wealth Management Inc. bought a new position in Takeda Pharmaceutical during the 4th quarter worth $52,000. EverSource Wealth Advisors LLC grew its stake in Takeda Pharmaceutical by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock worth $69,000 after buying an additional 1,770 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in Takeda Pharmaceutical by 85.5% during the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock worth $78,000 after buying an additional 2,411 shares during the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded up $0.12 during trading on Wednesday, hitting $15.14. The stock had a trading volume of 1,629,468 shares, compared to its average volume of 1,992,140. The business has a fifty day moving average of $14.86 and a two-hundred day moving average of $14.35. The firm has a market cap of $48.17 billion, a P/E ratio of 68.82 and a beta of 0.23. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.01 and a quick ratio of 0.52. Takeda Pharmaceutical Co. has a fifty-two week low of $12.80 and a fifty-two week high of $16.00.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). The business had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. On average, sell-side analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.